ReviewBreast cancer research : BCR2015
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics.
Review in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 2 syntheses or guidelines pooled it, 370 citations in OpenAlex.
- Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance.The Journal of clinical investigation · 2026Review
- Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.Breast cancer (Tokyo, Japan) · 2026Article
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Artificial Intelligence for Diagnostic and Prognostic Support in Breast Cancer: A Literature Overview.Cancers · 2026Review
- Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.Journal of breast cancer · 2026Article
- Germline Multigene Panel Testing in Women With Invasive Lobular Cancer.JAMA network open · 2026Article
- Case report of invasive lobular carcinoma with pineal metastasis.Oxford medical case reports · 2026Article
- Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer.Annals of surgical oncology · 2026Article
- Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier status.NPJ digital medicine · 2026Article
- LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.Cancer research · 2026Article
- Margin status after breast-conserving surgery for breast cancer in the Netherlands from 2009 to 2022.BJS open · 2026Article
- When Breast Cancer Hides Elsewhere: Invasive Lobular Carcinoma Presenting as Gallbladder Disease.Cureus · 2026Article
- Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programs.NPJ breast cancer · 2026Article
- Age-stratified analysis of invasive lobular carcinoma reveals comparable clinicopathological and molecular features across age groups.Discover oncology · 2026Article
- Metastatic breast cancer presenting with dyspeptic symptoms: a case report.Journal of medical case reports · 2026Article
- Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis.Frontiers in oncology · 2026Article
- The Roles of MicroRNAs, Oncogenes, and Tumor Suppressor Gene Molecular Subtypes of Breast Cancer: Therapeutic Potential of Pharmaceutical and Natural Products.International journal of breast cancer · 2026Review
135 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular carcinoma of the breast is the most common 'special' morphological subtype of breast cancer, comprising up to 15% of all cases. Tumours are generally of a good prognostic phenotype, being low histological grade and low mitotic index, hormone receptor positive and HER2, p53 and basal marker negative, and with a generally good response to endocrine therapy. Despite this, clinicians face countless challenges in the diagnosis and long-term management of patients, as they encounter a tumour that can be difficult to detect through screening, elicits a very invasive nature, a propensity for widespread metastatic colonisation and, consequently, in some studies a worse long-term poor outcome compared with invasive carcinoma of no special type. Here we review the morphological and molecular features that underpin the disparate biological and clinical characteristics of this fascinating tumour type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.